Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice

Author:

Chojecki Aleksander1,Boselli Danielle1,Dortilus Allison1,Hamadeh Issam2,Begley Stephanie1,Chen Tommy1,Bose Rupali1,Podoltsev Nikolai3,Zeidan Amer3,Balmaceda Nicole Baranda4,Yacoub Abdulraheem4,Ai Jing1,Knight Thomas Gregory1,Ragon Brittany Knick1,Shah Nilay1,Sanikommu Srinivasa Reddy1,Symanowski James1,Mesa Ruben1,Grunwald Michael1

Affiliation:

1. Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine

2. Memorial Sloan Kettering Cancer Center

3. Yale New Haven Hospital

4. University of Kansas Medical Center

Abstract

Abstract

Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by unregulated red blood cell production resulting in elevated hemoglobin (HGB) and/or hematocrit (HCT). Patients often have clinical symptoms such as fatigue, pruritus, and painful splenomegaly but are also at increased risk of thrombosis, both venous and arterial. Ruxolitinib, a selective JAK inhibitor, is approved by the US Food and Drug Administration as second-line cytoreductive treatment after intolerance or inadequate response to hydroxyurea. Though ruxolitinib has been widely used in this setting, limited data exist in the literature on ruxolitinib treatment patterns and outcomes among patients with PV in routine clinical practice. We report a retrospective, observational, cohort study of patients treated for PV with ruxolitinib across three US centers (academic and regional practice) from December 2014-December 2019. We identified 69 patients with a median follow-up was 3.7 years (95% CI, 2.9 to 4.4). Our data demonstrate very high rates of HCT control (88% of patients by three months and 89% by six months); few patients required dose adjustments or suspension during the study period. No arterial thromboses were observed and we found that one patient had a thrombotic event in the setting of a second malignancy. We also found that 28% of patients initiated ruxolitinib as a result of poorly controlled platelet counts, second only to hydroxyurea intolerance (46%). In clinical practice, ruxolitinib continues to be effective in controlling HCT after three and six months of treatment in patients with low thrombotic risk.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3